Home' Australian Pharmacist : Australian Pharmacist December2016 Contents Australian Pharmacist December 2016 I © Pharmaceutical Society of Australia Ltd.
CONTINUING PROFESSIONAL DEVELOPMENT
1. Polypharmacy has been associated
with which of the following?
a) Cognitive impairment.
d) All of the above.
2. Which of the following statements is
a) Polypharmacy is usually defined as the
use of five or more drugs.
b) The more drugs a patient is prescribed,
the less likely they are to be prescribed
c) Ceasing medicines is less complicated
than initiating treatment.
d) Once medicines are initially prescribed
for a patient, they will always be
3. Which of the following statements
about the deprescribing process is
a) Once a medicine is ceased, ongoing
monitoring is no lo nger required.
b) STOPP criteria can be used to identify
potentially inappropriate medicines in
c) Patient consent and education is
not necessary when deprescribing
d) Obtaining a medication history
will involve details of prescription
4. The potential harms of deprescribing
a) Pharmacokinetic changes of other
medicines being taken.
b) Increased risk of falls.
c) Withdrawal symptoms.
d) a) and c).
Australian Pharmacist Continuing Professional
Development (CPD) is a central element of PSA’s
CPD & PI program.
The CPD section is recognised under the PSA
CPD & PI program as a Group 2 activity. Members
can choose which articles they want to answer
questions on and get CPD credits based on the
questions they answer.
CPD credits are allocated based on the length of
the article and the complexity of the information
presented. A minimum of 6 out of 8 questions, 4 out
of 5 questions, or 3 out of 4 questions correct is
required for the allocation of Group 2 CPD credits.
PSA members can answer online at www.psa.org.au.
Login to submit your answers online. If you
do not have member access details, you can
request them via a link from the login page.
• Select 'Professional development and assessment'
• Select 'Submit answers'
• Select 'Australian Pharmacist'
Submit your answers online at www.psa.org.au
and receive automatic feedback. CPD credits
will be available until 1 December 2018.
1. Hilmer S. The dilemma of polypharmacy. Aust Prescr
2. Steinman MA, Landefeld CS, Rosenthal GE, et al.
Polypharmacy and prescribing quality in older people. J Am
Geriatr Soc 2006;54(10):1516–23.
3. Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly
patients. Am J Geriatr Pharmacother 2007;5(4):345–51.
4. Reeve E, Shakib S, Hendrix I, et al. The benefits and harms of
deprescribing. Med J Aust 2014;201(7):386–9.
5. Rochon PA, Gurwitz JH. Optimising drug treatment
for elderly people: the prescribing cascade. BMJ
6. Akazawa M, Imai H, Igarashi A, et al. Potentially
inappropriate medication use in elderly Japanese patients.
Am J Geriatr Pharmacother. 2010;8(2):146–60 .
7. Eckert KA, Shi Z, Taylor AW, et al. Learning from an
epidemiological, population-based study on prescribed
medicine use in adults. Pharmacoepidemiol Drug Saf
8. Bourgeois FT, Shannon MW, Valim C, et al. Adverse drug
events in the outpatient setting: an 11-year national
analysis. Pharmacoepidemiol Drug Saf. 2010;19(9):901–10.
9. Doan J, Zakrzewski-Jakubiak H, Roy J, et al. Prevalence
and risk of potential cytochrome P450-mediated drug-
drug interactions in older hospitalized patients with
polypharmacy. Ann Pharmacother 2013;47(3):324–32.
10. Lindblad CI, Artz MB, Pieper CF, et al. Potential drug-disease
interactions in frail, hospitalized elderly veterans. Ann
Pharmacother 2005;39(3):412–7 .
11. Salazar JA, Poon I, Nair M. Clinical consequences of
polypharmacy in the elderly: expect the unexpected, think
the unthinkable. Expert Opin Drug Saf 2007;6(6):695–704.
12. Rollason V, Vogt N. Reduction of polypharmacy in the
elderly: a systematic review of the role of the pharmacist.
Drugs Aging 2003;20(11):817–32 .
13. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of
polypharmacy in elderly. Expert Opin Drug Saf 2014;13(1):
14. Tromp AM, Pluijm SM, Smit JH, et al. Fall-risk screening test:
a prospective study on predictors for falls in community-
dwelling elderly. J Clin Epidemiol 2001;54(8):837–44 .
15. Damián J, Pastor-Barriuso R, Valderrama-Gama E, et al.
Factors associated with falls among older adults living in
institutions. BMC Geriatr 2013;13:6.
16. Catic AG. Identification and management of in-hospital
drug-induced delirium in older patients. Drugs Aging
17. Martin NJ, Stones MJ, Young JE, et al. Development of
delirium: a prospective cohort study in a community
hospital. Int Psychogeriatr 2000;12(1):117–27.
18. Jyrkkä J, Enlund H, Lavikainen P, et al. Association of
polypharmacy with nutritional status, functional ability
and cognitive capacity over a three-year period in
an elderly population. Pharmacoepidemiol Drug Saf
19. Gormley EA, Griffiths DJ, McCracken PN, et al. Polypharmacy
and its effect on urinary incontinence in a geriatric
population. Br J Urol 1993;71(3):265–9 .
20. Woodward MC. Deprescribing: achieving better health
outcomes for older people through reducing medications.
J Pharm Pract Res 2003;33:323–8 .
21. Mansur N, Weiss A, Beloosesky Y. Relationship of in-
hospital medication modifications of elderly patients to
postdischarge medications, adherence, and mortality. Ann
22. Fuat A, Hungin AP, Murphy JJ. Barriers to accurate diagnosis
and effective management of heart failure in primary care:
qualitative study. BMJ 2003;326(7382):196.
23. Iyer S, Naganathan V, McLachlan AJ, et al. Medication
withdrawal trials in people aged 65 years and older: a
systematic review. Drugs Aging 2008;25(12):1021–31.
24. McKellar GE, Hampson R, Tierney A, et al. Nonsteroidal
antiinflammatory drug withdrawal in patients with stable
rheumatoid arthritis. J Rheumatol 2011;38(10): 2150–2 .
25. Ekbom T, Lindholm LH, Odén A, et al. A 5-year prospective,
observational study of the withdrawal of antihypertensive
treatment in elderly people. J Intern Med 1994;235(6):581–8.
26. Ballard C, Hanney ML, Theodoulou M, et al. The dementia
antipsychotic withdrawal trial (DART-AD): long-term follow-
up of a randomised placebo-controlled trial. Lancet Neurol
2009; 8(2):151–7 .
27. Reeve E, Wiese MD, Hendrix I, et al. People’s attitudes, beliefs,
and experiences regarding polypharmacy and willingness to
deprescribe. J Am Geriatr Soc 2013;61(9): 1508–14.
28. Reeve E, To J, Hendrix I, et al. Patient barriers to and enablers
of deprescribing: a systematic review. Drugs Aging
29. Molloy DW, Clarnette R. Standardized mini-mental state
examination (SMMSE): a user’s guide. Troy, NY: New Grange
30. Rossi S, ed. Australian medicines handbook. Adelaide:
Australian Medicines Handbook; 2016.
31. Pandolfino J. Discontinuation of proton pump inhibitor
therapy and the role of esophageal testing. Gastroenterol
Hepatol (N Y) 2013;9(11):747–9 .
32. Sansom LN, ed. Australian pharmaceutical formulary and
handbook. 23rd edn. Canberra: Pharmaceutical Society of
Links Archive Australian Pharmacist November 2016 Australian Pharmacist January 2017 Navigation Previous Page Next Page